Title: Monitoring for 5-aminosalicylate toxicity: prognostic model development and validation.

Short title: Monitoring for 5-aminosalicylate toxicity

Authors: A Abhishek (https://orcid.org/0000-0002-3859-7354)¹^, Matthew J Grainge², Tim Card², Maarten W Taal (https://orcid.org/0000-0002-3859-7354)¹^, Matthew J Grainge², Tim Card², Maarten W Taal (https://orcid.org/0000-0003-3924-4830)¹, Christopher P Fox⁵, Christian D Mallen⁶, Matthew D Stevenson², Richard D Riley⁶.

Author contact details:

A Abhishek: abhishek.abhishek@nottingham.ac.uk

Georgina Nakafero: georgina.nakafero@nottingham.ac.uk

Matthew J Grainge: matthew.grainge@nottingham.ac.uk

Tim Card: tim.card@nottingham.ac.uk

Maarten W Taal: mdzmt@exmail.nottingham.ac.uk

Guruprasad P Aithal: guru.aithal@nottingham.ac.uk

Christopher P Fox: Christopher.Fox2@nuh.nhs.uk

Christian D Mallen: c.d.mallen@keele.ac.uk

Matthew D Stevenson: m.d.stevenson@sheffield.ac.uk

Richard D Riley: <u>r.d.riley@bham.ac.uk</u>

Address: ¹School of Medicine, University of Nottingham, Nottingham NG5 1PB, UK. ²Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham NG5 1PB, UK. ³Centre for Kidney Research and Innovation, Translational Medical Sciences, School of Medicine, University of Nottingham, Derby DE22 3NE, UK. ⁴Nottingham Digestive Diseases Centre, Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham NG7 2UH, UK. ⁵Department of Haematology, Nottingham University Hospital NHS Trust, Nottingham NG5 1PB, UK. ⁶Primary Care Centre Versus Arthritis, Keele University, Keele ST5 5BJ, UK. ⁷School of Health and Related Research, University of Sheffield, Sheffield S1 4DA. ⁸Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK.

Corresponding author: Prof. Abhishek. **Address for correspondence:** A23, City Hospital Nottingham, The University of Nottingham, Nottingham NG5 1PB, UK.

Entail his preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Background and aim: To develop and validate a prognostic model for risk-stratified

monitoring of 5-aminosalicylate (5-ASA) toxicity.

Methods: This nationwide retrospective cohort study used data from the Clinical

Practice Research Datalink (CPRD) Aurum and Gold for model development and

validation respectively. It included adults newly diagnosed with inflammatory bowel

disease (IBD) and established on 5-ASAs between 01/01/2007 and 31/12/2019. 5-

ASA discontinuation with abnormal monitoring blood test result was the outcome of

interest. Patients prescribed 5-ASAs for ≥6 months i.e., established on treatment, were

followed-up for up to five years. Penalised Cox-regression was used to develop the

risk equation. Model performance was assessed in terms of calibration and

discrimination. Statistical analysis was performed using STATA (StataCorp LLC).

Results: 14,109 and 7,523 participants formed the development and validation cohorts

with 401 and 243 events respectively. 185, 172, and 64 discontinuations were due to

cytopenia, elevated creatinine and elevated liver enzymes respectively in the

derivation cohort. Hazardous alcohol intake, chronic kidney disease, thiopurine use,

and blood test abnormalities before follow-up were strong prognostic factors. The

optimism adjusted R²_D in development data was 0.08. The calibration slope and

Royston D statistic (95% Confidence Interval) in validation cohort were 0.90 (0.61-

1.19) and 0.57 (0.37-0.77) respectively.

Conclusion: This prognostic model utilises information available during routine clinical

care and can be used to inform decisions on the interval between monitoring blood-

tests. The results of this study ought to be considered by guideline writing groups to

2

risk-stratify blood test monitoring during established 5-ASA treatment.

Keywords: 5-aminosalicylate, nephritis, hepatotoxicity, myelotoxicity

Funding This research was funded by National Institute for Health and Care Research (NIHR) grant NIHR130580. The funders had no role in conducting and/or reporting this study.

What is already known?

- Renal, hepatic and blood toxicity are uncommon during long-term 5-aminosalicylate (5-ASA)
 treatment.
- There are no mechanisms to predict the risk of these toxicities during established treatment that may be used to risk stratify blood-test monitoring.

What this study adds?

- Using a large national dataset originated during routine care, this study developed a
 prognostic model that discriminated patients at varying risk of 5-ASA toxicity during
 established treatment with good performance characteristics validated.
- Most patients were at low-risk of toxicity due to 5-ASAs and could continue with annual monitoring blood-tests while others at high risk may require more frequent monitoring.
- This prognostic model can be used to make an informed decision on the interval between monitoring blood tests and the findings ought to be considered by guideline writing groups to bring about equitable and sustainable change in clinical practice.

Introduction 5-aminosalicylates (5-ASA) are the mainstay of treatment for mild to

moderate ulcerative colitis and are often combined with biologics in the treatment of

severe disease¹⁻³. Although effective, they can cause side-effects such as interstitial

nephritis, hepatitis and blood-dyscrasias⁴⁻²⁰. These side-effects are common early

during the treatment¹⁷⁻¹⁹ but they also occur later. For instance, the median time to

development of interstitial nephritis ranged between 2.3 and 3 years in published

studies^{8 9}. There is substantial variation in recommendations on screening for the

occurrence of myelotoxicity, hepatotoxicity, and nephrotoxicity during established 5-

ASA treatment.

For instance, the summary of product characteristics recommends three monthly full

blood count (FBC), liver function test (LFT), and urea electrolytes and creatinine

(UE&C) during established treatment¹⁹, whereas the European consensus from the

European Crohn's and Colitis Organisation is to monitor with FBC and UE&C at three

to six monthly intervals³, while the American Gastroenterology Association and the

British Society of Gastroenterology recommend monitoring with UE&C periodically

and annually respectively during established treatment¹ ². This latter may be

4

disadvantageous to patients treated with 5-ASA drugs due to their well-documented

but uncommon myelotoxicity and hepatotoxicity.

Due to the rarity of cytopenia, hepatotoxicity and nephrotoxicity due to 5-ASA⁴⁻⁶ 16, It

would be beneficial to predict clinically significant renal, hepatic or myelotoxicity during

established treatment to allow risk-stratified monitoring. This study developed and

validated a prognostic model for clinically significant 5-ASA toxicity during established

treatment.

Methods <u>Data source:</u> Data from the Clinical Practice Research Datalink (CPRD)

Aurum and Gold were used for model development and validation respectively ²¹ ²².

CPRD is an anonymised longitudinal database of electronic health records collected

during routine clinical care in the NHS. With almost universal coverage of UK

residents, participants that contributed data to the CPRD are representative of the UK

population ²¹. CPRD Aurum and Gold complement each other in terms of coverage of

general practices according to the use of different software for data capture. Some

general practices that have contributed data to both databases were only included in

the model development cohort.

Approvals: ISAC of the MHRA (Reference: 20_000236R).

Study design: Retrospective cohort study.

Study period: 1st January 2007 to 31st December 2019.

Study population: Participants aged ≥18 years with a new diagnosis of inflammatory

bowel disease (IBD) newly prescribed 5-ASA by their GP for at-least six-months were

eligible (Supplementary methods). Patients with severe liver, kidney or haematological

diseases prior to first 5-ASA prescription were excluded as described previously²³.

Follow-up: Patients were followed-up from 180 days after their first GP prescription

until the earliest of outcome, death, transfer out of practice, 90-days prescription gap,

last data collection from practice, 31/12/2019 or five-years from the start of follow-up.

Outcome: 5-ASA-toxicity associated drug discontinuation was the outcome of interest.

This was defined as a prescription gap of ≥90 days with either an abnormal blood-test

result (either leucocyte count <3.5×10⁹/L, or neutrophil count <1.6×10⁹/L, or platelet

6

count <140×109/L, or alanine transaminase and/or aspartate transaminase >100

IU/mL, or decline in kidney function, defined as either progression of chronic kidney

disease (CKD) based on medical codes recorded by the GP, or >26 µmol/L increase

in creatinine concentration, the threshold for consideration of acute kidney injury

(AKI)²⁴) or a diagnostic code for abnormal blood-test result within ±60 days of the last

prescription date^{23 25}.

A random sample of 5-ASA discontinuations with abnormal blood test results was

drawn. Data for all diagnostic codes entered during primary-care consultations within

±60 days of the abnormal blood test result were extracted. A.A. screened the list to

identify outcomes that could potentially be explained by an alternative condition or its

treatment.

<u>Predictors</u> were selected based on clinical expertise and knowledge of the published

literature (Table 1). Age, sex, body mass index (BMI), alcohol intake, and diabetes

were included as they associate with drug induced liver injury (DILI) ²⁶ ²⁷. CKD was

included as it reduces 5-ASA clearance²⁸. Statins, carbamazepine, valproate,

paracetamol were included as their use is associated with 5-ASA toxicity relevant to

this study²⁸. Methotrexate, leflunomide, thiopurines were included as they can cause

cytopenia, elevated liver enzymes and AKI. Either cytopenia (neutrophil count <2 x

 $10^9/I$, or total leucocyte count <4 x $10^9/I$, or platelet count <150 $10^9/I$) or elevated

transaminase (ALT and/or AST >35 IU/I) during the first six months of primary care

prescription were included as they predicted cytopenia and/or transaminitis in other

studies 29 30.

Sample size: The incidence of toxicity from 5-ASA ranged between 1.2 and 1.7 per

1,000 person-years for interstitial nephritis⁵ ⁶. To minimise model overfitting and

ensure precise estimation of overall risk, the minimum sample size required for new

model development was 2,590 participants (39 events) based on a maximum of 20

parameters, Cox-Snell R² value of 0.12, estimated event rate of 0.005/person-year, a

5-year time horizon, and a mean follow-up period of 3 years using the formulae of

Riley et al.,³¹. The sample size for external model validation was larger than the

typically recommended minimum sample size of 200 events³².

Statistical analysis: Multiple imputation handled missing data on BMI and alcohol

intake using chained equations ³³. We carried out 10 imputations in the development

dataset and 5 imputations in the validation dataset - a pragmatic approach considering

the large size of CPRD. The imputation model included all candidate predictors,

baseline Nelson-Aalen cumulative hazard function and outcome variable.

Model development: Fraction polynomial regression (first degree) analysis was used

to model non-linear risk relationships with continuous predictors, but these were not

better than the linear terms (p > 0.05), hence were not transformed. All candidate

predictors and parameters were included in the Cox model and coefficients of each

parameter estimated and combined using Rubin's rule across the imputed datasets.

The risk equation for predicting an individual's risk of 5-ASA discontinuation with

abnormal blood-test results by 5-years follow-up was formulated in the development

data. The baseline survival function at t=5 years, a non-parametric estimate of survival

function when all predictor values are set to zero, which is equivalent to the Kaplan-

Meier product-limit estimate, was estimated along with the estimated regression

coefficients (β) and the individual's predictor values (X). This led to the equation for

the predicted absolute risk over time ³⁴:

Predicted risk = $1 - S_0(t_{-5})^{exp(X\beta)}$ where $S_0(t_{-5})$ is the baseline survival function at 5-

8

years of follow-up and βX is the linear predictor, $\beta_1 x_1 + \beta_2 x_2 + ... + \beta_p x_p$.

Model internal validation and shrinkage: The performance of the model in terms of

calibration was assessed by plotting agreement between predicted and observed

outcomes. Internal validation was performed to correct performance estimates for

optimism due to overfitting by bootstrapping with replacement 500 samples of the

development data. The full model was fitted in each bootstrap sample and then its

performance was quantified in the bootstrap sample (apparent performance) and the

original sample (test model performance), and the optimism calculated (difference in

test performance and apparent performance). A uniform shrinkage factor was

estimated as the average of calibration slopes from the bootstrap samples. This

process was repeated for all 10 imputed datasets, and the final uniform shrinkage

calculated by averaging across the estimated shrinkage estimates from each

imputation. Optimism-adjusted estimates of performance for the original model were

then calculated, as the original apparent performance minus the optimism.

To account for overfitting, the original β coefficients were multiplied by the final uniform

shrinkage factor and the baseline hazards re-estimated conditional on the shrunken β

coefficients to ensure that overall calibration was maintained, producing a final model.

The D statistic, a measure of discrimination, interpreted as a log hazard ratio (HR) 35

³⁶, and R², a measure of variation explained by the model were calculated.

Model external validation: The final developed model equation was applied to the

validation dataset, and calibration and discrimination were examined³⁵ ³⁶. Calibration

of 5-year risks was examined by plotting agreement between estimated risk from the

model and observed outcome risks. In the calibration plot, predicted and observed

risks were divided into 10 equally sized groups. Pseudo-observations were used to

construct smooth calibration curves across all individuals via a running non-parametric

smoother. Separate graphs were plotted for each imputation. Stata-MP version 16 was used for statistical analyses. This study was reported in line with the TRIPOD guidelines 37.

Results *Participants:* Data for 14,109 and 7,523 participants that contributed 41,146 and 21,070 person-years follow-up were included in the development and validation cohorts, respectively (Figure S1 and S2). Over 97% participants were diagnosed with IBD alone, over 50% self-identified as male, and had similar lifestyle factors, comorbidities, and drug treatments (Table 1). Twelve candidate predictors (17 predictor parameters) were included in the model (Table 2).

Model development: In the derivation dataset, 401 outcomes occurred in 2.8% patients (n=14,109) during follow-up at a rate (95% CI) of 9.75 (8.84 – 10.75) per 1,000 personyears. Outcome validation exercise in 167 outcomes revealed that only 10.2% outcomes (n=17) could potentially be explained by another contemporaneous illness or its treatments, with a positive predictive value of 89.8% (Table S1). Cytopenia, increase in serum creatinine, and elevated liver enzymes caused 5-ASA discontinuation in 185, 172, and 64 participants respectively (Figure S3). CKD-3, thiopurine co-prescription, hazardous alcohol use, ex-alcohol use and either cytopenia or elevated liver enzymes during first six months of 5-ASA prescription were strong predictors of drug discontinuation with adjusted hazard ratio (95% confidence interval (CI)) 2.31 (1.68,3.17), 2.09 (1.59,2.74), 1.85 (1.25,2.74), 1.53 (1.06,2.21) and 1.56 (1.18,2.16) respectively (Table 2). Before shrinkage, the calibration slope in the derivation data was 1.00 (95% CI 0.82-1.18). From the bootstrap, a uniform shrinkage factor of 0.83 was obtained and used to shrink predictor coefficients in the final model for optimism and after re-estimation, the final model's cumulative baseline survival function (S₀) was 0.971 at 5-years of follow-up (Box 1).

Model performance in the derivation cohort: Calibration plot of the final (i.e., after shrinkage) model at 5-years showed that the average model predictions matched the average observed outcome probabilities across 10 groups of patients, with confidence intervals overlapping the 45-degree line (perfect prediction line) (Figure 1). As most patients had low risk of outcome, most of the deciles clustered at the bottom left of the calibration plot (Figure S4). The smoothed calibration curve at 5-years showed alignment of observed risk to the predicted risk with wide confidence intervals at >0.1 risk probabilities (Figure 1, Figure S5). Royston *D* statistic (95% CI) was 0.75 (0.59,0.91) corresponding to HR 2.12 (1.80-2.48) when comparing the risk groups above and below the median of linear predictor. The optimism adjusted Royston *D* statistic was 0.60 corresponding to HR 1.82, obtained by exponentiating the D statistic (Table 3).

Model performance in the validation cohort: There were 243 outcomes in 3.2% (n=7,523) patients at a rate (95% CI) of 11.53 (10.17-13.08) per 1000 person-years in the validation cohort. The calibration slope (95% CI) across the five-year follow-up period was 0.90 (0.61-1.19). The calibration plot showed reasonable correspondence between observed and predicted risk at 5-years across the tenths of risk with confidence intervals crossing the perfect prediction line (Figure S6). Most groups clustered at the bottom left of the calibration plot owing to low risk of outcome for most patients (Figures S7). When individual risk was plotted, the smoothed calibration curve showed instability in the model predictions with a tendency to under-predict low risk by a small amount (Figure 2). Model performance was also tested at years 1, 2, 3 and 4 and showed a similar pattern (Figures S8-11). Model discrimination in the derivation and validation data was broadly similar (Table 3). The Royston D statistic in the

validation data was 0.57 (0.37,0.77), corresponding to HR (95% CI) 1.77 (1.45-2.16). The R^2 score was 0.07 (95% CI 0.03,0.12).

<u>Worked examples:</u> Ten anonymised patient profiles, one from the middle of each decile of predicted risk were selected from the development cohort (Table S2). The cumulative probability of outcome over five years ranged from 3.1% in the middle of the first group to 4.6% in the middle of the seventh group, and 8.6% in the middle of the 10th group.

Discussion This study developed and externally validated a prognostic model for 5-ASA discontinuation with abnormal monitoring blood test results. To the best of our knowledge this is the first such endeavour. The model was developed using a large real-world and nationally representative dataset that originated during routine care of patients and has high generalisability. It had good performance characteristics in an independent dataset. It predicted clinically relevant toxicity i.e., one that required 5-ASA treatment being stopped, indicating face validity. The prognostic factors were selected to include those that are readily available during routine consultations. This makes the model is easy to use.

5-ASAs were stopped for cytopenia, elevated creatinine and elevated liver enzymes suggesting that monitoring blood-tests should include FBC, UE&C, and LFT. Numerically more patients discontinued 5-ASA due to cytopenia than due to nephrotoxicity, with far fewer participants stopping treatment due to elevated liver enzymes. In another previous study, there were numerically greater number of blood-dyscrasias than AKI with relatively few instances of elevated liver enzymes⁴. Similarly, a French pharmacovigilance study in which spontaneously reported adverse events were included and causality assessment was performed reported numerically more cases with myelotoxicity (n=7) and either hepatitis or elevated liver enzymes (n=7) than renal insufficiency (n=2) over a one-year period¹⁶. 5-ASA drugs are believed to be less hepatotoxic than sulfasalazine, however, the cumulative occurrence of drug induced liver injury was similar in the mesalazine and sulfasalazine arms of a randomised controlled trial, with 2.6% of patients taking mesalazine experiencing liver injury²⁰. In another study, the mean white blood cell count reduced significantly with 5-

ASA treatment, while the mean levels of creatinine and liver enzymes remained

unchanged¹⁵. Thus, the findings of our study are consistent with previous reports.

CKD-3, hazardous and prior-alcohol use were strong independent predictors of 5-ASA

discontinuation with blood-test abnormalities. These are novel findings. Nevertheless,

these are plausible predictors. Co-prescription of a thiopurine was a strong risk-factor

for toxicity consistent with other studies³⁸⁻⁴⁰. Abnormal blood-test results during the

first six months of therapy were strong independent predictors of discontinuing 5-ASA

with abnormal monitoring blood-test results, like previous reports about other drugs²³

41

However, several limitations of this study ought to be considered. First, information

about the date when 5-ASA was first prescribed from hospital was unavailable. This

is not a serious issue as the model can be applied once the patient has completed six-

months of 5-ASA treatment from primary-care after treatment initiation and initial

stabilization in a hospital clinic, or approximately one year from first prescription in a

healthcare system without shared care prescription. Second, we did not have

information on the use of biologics as these are hospital prescribed. Third, data on

disease activity are not recorded in the CPRD. Fourth, we could not consider ulcerative

colitis and Crohn's disease as separate prognostic factors as it is not possible to

reliably differentiate between them in the CPRD. Fifth, the abnormal blood test could

be due to a different illness. Although in our previous validation studies, only 5.4% of

abnormal blood-test results could be explained by an alternative illness ²⁵. Sixth,

although the external validation dataset was distinct from the model development

dataset, it also originated from UK. We recommend that our model be validated in a

dataset from another country. Seventh, there were 9 (0.06%) patients in the highest

three tenths of risk resulting in uncertainty regarding predictors for these groups.

Eighth, we did not perform competing risk regression. However, this does not limit the

validity of our findings as there were few deaths (26 [0.18%]) in the derivation and (10

[0.13%]) validation cohorts up to the 5-year follow-up.

In conclusion, we have developed and externally validated a prognostic model for 5-

ASA discontinuation with abnormal monitoring blood test results that may be used to

individualise monitoring using principles of shared decision making between the

patient and the physician. These findings need to be considered by guideline writing

16

groups to bring about sustained change in clinical practice.

Author contributions:

A Abhishek: the conception and design of the study, interpretation of data, drafting the

article, revising article critically for important intellectual content, final approval of the

version to be submitted.

Georgina Nakafero: the conception and design of the study, analysis and interpretation

of data, assisted in drafting the article, revising article critically for important intellectual

content, final approval of the version to be submitted.

Matthew J Grainge: the conception and design of the study, interpretation of data,

revising article critically for important intellectual content, final approval of the version

to be submitted.

Tim Card: the conception and design of the study, interpretation of data, revising

article critically for important intellectual content, final approval of the version to be

submitted.

Maarten W Taal: the conception and design of the study, interpretation of data,

revising article critically for important intellectual content, final approval of the version

to be submitted.

Guruprasad P Aithal: the conception and design of the study, interpretation of data,

revising article critically for important intellectual content, final approval of the version

to be submitted.

Christopher P Fox: the conception and design of the study, interpretation of data,

revising article critically for important intellectual content, final approval of the version

to be submitted.

Christian D Mallen: the conception and design of the study, interpretation of data,

revising article critically for important intellectual content, final approval of the version

17

to be submitted.

Matthew D Stevenson: the conception and design of the study, interpretation of data, revising article critically for important intellectual content, final approval of the version to be submitted.

Richard D Riley: the conception and design of the study, analysis and interpretation of data, revising article critically for important intellectual content, final approval of the version to be submitted.

Conflict of interest statement: A.A. has received Institutional research grants from AstraZeneca and Oxford Immunotech; and personal fees from UpToDate (royalty), Springer (royalty), Cadilla Pharmaceuticals (lecture fees), NGM Bio (consulting), Limbic (consulting) and personal fees from Inflazome (consulting) unrelated to the work. GP Aithal has received consulting fees from Abbott, Albereo, Amryth, AstraZeneca, BenevolentAI, DNDI, GlaxoSmithKline, NuCANA, Pfizer, Roche Diagnostics, Servier Pharmaceuticals, W.L Gore & Associates paid to the University of Nottingham unrelated to the work. CPF has received Consultancy/Advisory board fees from Abbvie, GenMab, Incyte, Morphosys, Roche, Takeda, Ono, Kite/Gilead, BMS/Celgene, BTG/Veriton and departmental research funding from BeiGene unrelated to the work. The other authors have no conflict of interest to declare.

Data availability statement: Data used in the study are from the Clinical Practice Research Datalink and cannot be shared due to licencing restrictions. Study protocol is available from www.cprd.com.

Table 1: Distribution of candidate predictors in development and validation cohorts

Predictor ¹	Derivation cohort (CPRD Aurum) n=14,109	Validation cohort (CPRD Gold) n=7,523
Age, mean (standard deviation) year	46.7 (17.6)	47.5 (17.7)
Male sex	7,253 (51.4)	3,866 (51.4)
Body mass index		
<18.5 kg/m ²	436 (3.1)	234 (3.1)
18.5-24.9 kg/m ²	5,033 (35.7)	2,540 (33.8)
25.0-29.9 kg/m ²	4,047 (28.7)	2,247 (29.9)
≥30 kg/m²	2,660 (18.7)	1,482 (19.7)
Missing	1,933 (13.7)	1,020 (13.6)
Alcohol use		,
Non-user	2,373 (16.8)	936 (12.4)
Low (1-14 units/week)	5,838 (41.4)	3,815 (50.7)
Moderate (15-21 units/week)	847 (6.0)	429 (5.7)
Hazardous (>21 units/week)	1,024 (7.3)	419 (5.6)
Ex-user	1,075 (7.6)	400 (5.3)
Missing	2,952 (20.9)	1,524 (20.3)
Inflammatory conditions		,
Inflammatory bowel disease alone	13,728 (97.3)	7,318 (97.3)
Psoriasis	276 (2.0)	141 (1.9)
Autoimmune rheumatic disease ² Comorbidities	105 (0.7)	64 (0.9)
Diabetes	1,099 (7.8)	582 (7.7)
Chronic kidney disease stage-3 Immunosuppressive drugs	827 (5.9)	4.8 (5.4)
Thiopurine	1,336 (9.5)	814 (10.8)
Methotrexate/leflunomide	64 (0.5)	24 (0.3)
Other drugs	,	,
Statins	2,078 (14.7)	1,124 (14.5)
Carbamazepine/valproate	119 (0.8)	74 (Ì.0)
Paracetamol	1,001 (7.1)	653 (8.7)
At least mild cytopenia or liver	973 (6.9)	516 (6.9)
enzyme elevation in six-months preceding start of follow-up	()	,

¹Values are numbers (percentage) unless stated otherwise. ²Rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis/Reactive arthritis. CPRD: Clinical Practice Research Datalink.

Table 2: Final model hazard ratios and β-coefficients before penalisation

Table 2: Final model nazard ratios		•
Predictors	Adjusted HR	Coefficients
	(95% CI)	
Age, year	1.00 (1.00,1.01)	.0016945
Female sex	1.01 (0.82, 1.24)	.0082816
Body mass index (kg/m²)	1.00 (0.98,1.02)	.0020271
Alcohol use	,	
Non-user	Reference	-
Low (1-14 units/week)	0.99 (0.73,1.33)	0106059
Moderate (15-21 units/week)	1.10 (0.69,1.77)	.0982098
Hazardous (>21 units/week)	1.85 (1.25,2.74)	.6161676
Ex-user	1.53 (1.06,2.21)	.4275329
Inflammatory conditions		
Inflammatory bowel disease	Reference	-
Psoriasis	1.21 (0.62,2.35)	.1917626
Autoimmune rheumatic disease ²	1.27 (0.44,3.67)	.2380761
Comorbidities		
Diabetes	1.15 (0.81,1.63)	.1383201
Chronic kidney disease stage-3	2.31 (1.68,3.17)	.8360309
Immunosuppressive drugs		
None	Reference	-
Thiopurine	2.09 (1.59,2.74)	.7359997
Methotrexate/Leflunomide	1.85 (0.54,6.29)	.6131115
Other drugs		
Statins	1.21 (0.91,1.61)	.1890031
Carbamazepine/valproate	1.29 (0.53,3.13)	.2554022
Paracetamol	1.26 (0.91,1.740	.231411
Blood-test abnormalities		
At least mild cytopenia or liver enzyme	1.56 (1.18,2.16)	.4665026
elevation in six-months preceding start	•	
of follow-up		

¹HR: hazard ratio, CI: confidence interval. ²Rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis/Reactive arthritis

Table 3: Model diagnostics

Measure	Apparent performance*	Test performance [†]	Average optimism‡	Optimism corrected performance§	External validation (CPRD Gold)
Overall calibration	1.00	0.83	0.17	0.83	0.90
slope	(0.82, 1.18)	(0.67, 0.99)			(0.61, 1.19)
R^2_D	0.12	0.11	0.04	0.08	0.07
	(0.08, 0.16)	(0.07, 0.14)			(0.03, 0.12)
Royston D statistic	0.75	0.69	0.15	0.60	0.57
-	(0.59, 0.91)	(0.54, 0.85)			(0.37, 0.77)

CPRD=Clinical Practice Research Datalink.

^{*} Estimated directly from data that was used to develop the model.

[†] Determined by executing full model in each bootstrap sample of the development dataset (500 samples with replacement), calculating bootstrap performance, and applying same model in original sample.

[‡] Average difference between model performance in bootstrap sample of the development dataset and performance in the development dataset.

[§] Obtained by subtracting average optimism from apparent performance.

Box 1: Equation to predict the risk of 5-ASA discontinuation after six months of primary care prescription and within the next 5-years.

Risk score = $1-0.971 \frac{\exp(0.83\beta X)}{\exp(0.83\beta X)}$, where $\beta X=0.0016945^*$ Age in years at first primary-care prescription + 0.0082816^* female-sex + 0.0020271^* body mass index - 0.0106059^* low alcohol intake + 0.0982098^* moderate alcohol intake + 0.6161676^* hazardous alcohol intake + 0.4275329 *Ex-alcohol intake + 0.1917626^* Psoriasis + 0.2380761^* autoimmune rheumatic disease + 0.1383201^* diabetes + 0.8360309^* Chronic kidney disease stage-3 + 0.7359997^* thiopurine + 0.6131115^* methotrexate or leflunomide + 0.1890031^* statins + 0.2554022^* Carbamazepine/valproate + 0.231411^* paracetamol + 0.4665026^* At-least mild cytopenia or liver enzyme elevation within first six-months of primary-care prescription.

All variables are code 0, and 1 if absent or present respectively, except for BMI and age that are continuous variables. 0.971 is the baseline survival function at 5-years, 0.83 is the shrinkage factor and the other numbers are the estimated regression coefficients for the predictors, which indicate their mutually adjusted relative contribution to the outcome risk. Thiopurines included either azathioprine or 6-mercaptopurine. Autoimmune rheumatic diseases included rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, reactive arthritis.

Figure 1: Calibration of a prognostic model for 5-ASA discontinuation with abnormal monitoring blood-test results at 5 years in the development cohort¹.

¹Data from a single imputed dataset was used; $S_0(t=5) = 0.971$





Figure 2: Calibration of a prognostic model for 5-ASA discontinuation with abnormal monitoring blood-test results at 5 years in the validation cohort¹. ¹Data from a single imputed dataset was used; So(t=5) =0.971



References:

- 1. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. *Gut* 2019;68(Suppl 3):s1-s106.
- 2. Ko CW, Singh S, Feuerstein JD, et al. AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis. *Gastroenterology* 2019;156(3):748-64.
- 3. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. *J Crohns Colitis* 2010;4(1):28-62.
- 4. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. *Gut* 2002;51(4):536-9.
- 5. Van Staa TP, Travis S, Leufkens HG, et al. 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. *Gastroenterology* 2004;126(7):1733-9.
- 6. Logan RF, van Staa TP. Sulphasalazine and mesalazine: serious adverse reactions reevaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. *Gut* 2003;52(10):1530; author reply 30-1.
- 7. Muller AF, Stevens PE, McIntyre AS, et al. Experience of 5-aminosalicylate nephrotoxicity in the United Kingdom. *Aliment Pharmacol Ther* 2005;21(10):1217-24.
- 8. Moss JG, Parry CM, Holt RCL, et al. 5-ASA induced interstitial nephritis in patients with inflammatory bowel disease: a systematic review. *Eur J Med Res* 2022;27(1):61.
- 9. Heap GA, So K, Weedon M, et al. Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. *J Crohns Colitis* 2016;10(2):149-58.
- 10. Farrell RJ, Peppercorn MA, Fine SN, et al. Mesalamine-associated thrombocytopenia. *Am J Gastroenterol* 1999;94(8):2304-6.
- 11. Frattini F, Crestani S, Vescovi PP, et al. Pure white cell aplasia induced by mesalazine in a patient with ulcerative colitis. *Hematology* 2013;18(3):181-2.
- 12. Turunen U, Elomaa I, Anttila VJ, et al. Mesalazine tolerance in patients with inflammatory bowel disease and previous intolerance or allergy to sulphasalazine or sulphonamides. *Scand J Gastroenterol* 1987;22(7):798-802.
- 13. Deltenre P, Berson A, Marcellin P, et al. Mesalazine (5-aminosalicylic acid) induced chronic hepatitis. *Gut* 1999;44(6):886-8.
- 14. Braun M, Fraser GM, Kunin M, et al. Mesalamine-Induced Granulomatous Hepatitis. Official journal of the American College of Gastroenterology | ACG 1999;94(7):1973-74.
- 15. Masuda H, Takahashi Y, Nishida Y, et al. Comparison of the effect of mesalazine and sulfasalazine on laboratory parameters: a retrospective observational study. *Eur J Clin Pharmacol* 2012;68(11):1549-55.
- 16. Marteau P, Nelet F, Le Lu M, et al. Adverse events in patients treated with 5-aminosalicyclic acid: 1993-1994 pharmacovigilance report for Pentasa in France. *Aliment Pharmacol Ther* 1996;10(6):949-56.
- 17. Corrigan G, Stevens PE. Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. *Aliment Pharmacol Ther* 2000;14(1):1-6.
- 18. Gisbert JP, González-Lama Y, Maté J. 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. *Inflamm Bowel Dis* 2007;13(5):629-38.
- 19. limited. TpU. Summary of Product Characteristics of Mesalazine 2023 [Available from: https://www.medicines.org.uk/emc/product/2827/smpc/print accessed 18th June 2021 2023.

- 20. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. *Bmj* 1989;298(6666):82-6.
- 21. Herrett E, Gallagher AM, Bhaskaran K, et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD). *International journal of epidemiology* 2015;44(3):827-36.
- 22. Wolf A, Dedman D, Campbell J, et al. Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum. *International journal of epidemiology* 2019;48(6):1740-40g.
- 23. Nakafero G, Grainge MJ, Williams HC, et al. Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK. *Bmj* 2023;381:e074678.
- 24. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. *Nephron Clin Pract* 2012;120(4):c179-84.
- 25. Nakafero G, Grainge MJ, Card T, et al. What is the incidence of methotrexate or leflunomide discontinuation related to cytopenia, liver enzyme elevation or kidney function decline? *Rheumatology* 2021;60(12):5785-94.
- 26. Chalasani N, Björnsson E. Risk factors for idiosyncratic drug-induced liver injury. *Gastroenterology* 2010;138(7):2246-59.
- 27. Safy-Khan M, de Hair MJH, Welsing PMJ, et al. Current Smoking Negatively Affects the Response to Methotrexate in Rheumatoid Arthritis in a Dose-responsive Way, Independently of Concomitant Prednisone Use. *J Rheumatol* 2021;48(10):1504-07.
- 28. Committee JF. British National Formulary. [85]. London: BMJ Group and Pharmaceutical Press; [2023].
- 29. Meijer B, Wilhelm AJ, Mulder CJJ, et al. Pharmacology of Thiopurine Therapy in Inflammatory Bowel Disease and Complete Blood Cell Count Outcomes: A 5-Year Database Study. *Ther Drug Monit* 2017;39(4):399-405.
- 30. Dirven L, Klarenbeek NB, van den Broek M, et al. Risk of alanine transferase (ALT) elevation in patients with rheumatoid arthritis treated with methotrexate in a DAS-steered strategy. *Clin Rheumatol* 2013;32(5):585-90.
- 31. Riley RD, Ensor J, Snell KIE, et al. Calculating the sample size required for developing a clinical prediction model. *BMJ* 2020;368:m441.
- 32. Riley RD, Debray TPA, Collins GS, et al. Minimum sample size for external validation of a clinical prediction model with a binary outcome. *Statistics in Medicine* 2021;40(19):4230-51.
- 33. Schafer JL. Multiple imputation: a primer. Stat Methods Med Res 1999;8(1):3-15.
- 34. Steyerberg EW. Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating. Cham, SWITZERLAND: Springer International Publishing AG 2019.
- 35. Royston P, Altman DG. External validation of a Cox prognostic model: principles and methods. *BMC Medical Research Methodology* 2013;13(1):33.
- 36. Cox DR. Note on Grouping. *Journal of the American Statistical Association* 1957;52(280):543-47.
- 37. Moons KG, Altman DG, Reitsma JB, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. *Annals of internal medicine* 2015;162(1):W1-73.
- 38. AlAskar D, AlSardi M, Al Sulais E, et al. Risk of neutropenia in inflammatory bowel disease patients treated with TNF inhibitors: A single-center, retrospective cohort study. Saudi J Gastroenterol 2020;26(4):210-5.
- 39. Lowry PW, Franklin CL, Weaver AL, et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. *Gut* 2001;49(5):656-64.
- 40. Mayberry H, Moshkovska T, Mayberry JF. Co-prescribing azathiopurine or 6-mercaptopurine and 5-aminosalicylate compounds in ulcerative colitis. *Inflamm Bowel Dis* 2009;15(2):190-2.

41. Nakafero G, Grainge MJ, Card T, et al. Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood tests during long-term treatment: cohort study using data from the Clinical Practice Research Datalink Gold and Aurum. Rheumatology (Oxford) 2022;61(7):2783-91.

Castion/Tonia			TRIPOD CHECKLIST PREDICTION MODEL Checklist Items	Dogo
Section/Topic Title and abstract			Checklist Item	Page
Title	1);V	Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted.	1
Abstract	2);V	Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions.	2;3
Introduction	<u> </u>		outcome, standard unarysis, resures, and conclusions.	
Background and	3a);V	Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models.	6;7
objectives	ЗЬ);V	Specify the objectives, including whether the study describes the development or validation of the model or both.	7
Methods				
Course of data	4a);V	Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, if applicable.	8
Source of data	4b);V	Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.	8
Participants	5a);V	Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres.	8
Participants	5b);V	Describe eligibility criteria for participants.	8
5c	5c);V	Give details of treatments received, if relevant.	8,9
Outcome	ба	;V	Clearly define the outcome that is predicted by the prediction model, including how and when assessed.	9,10
	5b);V	Report any actions to blind assessment of the outcome to be predicted.	n/a
D 11.	7a	;V	Clearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured.	10
Predictors	7b);V	Report any actions to blind assessment of predictors for the outcome and other predictors.	n/a
Sample size	8);V	Explain how the study size was arrived at.	10
Missing data	9);V	Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.	11
	0a	D	Describe how predictors were handled in the analyses.	11-14
~	0b	D	Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation.	11-14
Statistical	0c	V	For validation, describe how the predictions were calculated.	14
analysis methods	0d);V	Specify all measures used to assess model performance and, if relevant, to compare multiple models.	12, 14
	0e	V	Describe any model updating (e.g., recalibration) arising from the validation, if done.	n/a
Risk groups	11);V	Provide details on how risk groups were created, if done.	n/a
Development vs. validation	12	V	For validation, identify any differences from the development data in setting, eligibility criteria, outcome, and predictors.	11,14
Results	1	1		1
	3a);V	Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.	Fig S1,S2
_	3b);V	Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.	15, Table
	3c	V	For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors and outcome).	15, Table 1
Model	4a	D	Specify the number of participants and outcome events in each analysis.	15
development	4b	D	If done, report the unadjusted association between each candidate predictor and outcome.	Table 2
Model	5a	D	Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point).	Fig 1
specification	5b	D	Explain how to the use the prediction model.	17
Model performance	16);V	Report performance measures (with Cls) for the prediction model.	Page 15, 16, Table 3
Model-updating	17	V	If done, report the results from any model updating (i.e., model specification, model performance).	n/a
Discussion			periorimitee).	1
Limitations	18);V	Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).	19
	9a	v	For validation, discuss the results with reference to performance in the development data, and any other validation data.	15.16
Interpretation	9b);V	Give an overall interpretation of the results, considering objectives, limitations, results from similar studies, and other relevant evidence.	18,19
Implications	20);V	Discuss the potential clinical use of the model and implications for future research.	19,20
Other information		r, •	me potential of the model and implications for future resourch.	27,200

Supplementary information	21);V	Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets.	21
Funding	22);V	Give the source of funding and the role of the funders for the present study.	21